Tag: prospectus

마이애미, June 20, 2026 (GLOBE NEWSWIRE) --

, June 19, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs가 유럽 최초의 메모리 반도체 ETF인 Defiance Memory UCITS ETF(티커: DRAM)를 출시했다고 발표했다. 이 펀드는 메모리 반도체 및 데이터 저장 시스템의 개발, 제조, 상용화, 저장 기술과 관련된 기업들에 투자 기회를 제공하는 것을 목표로 한다.

TORONTO, June 19, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK), today announced updated investment risk ratings of the iShares ETFs listed below, effective as of June 19, 2026:

TORONTO, 19 juin 2026 (GLOBE NEWSWIRE) -- Gestion d’actifs BlackRock Canada Limitée (« BlackRock Canada »), filiale indirecte en propriété exclusive de BlackRock, Inc. (« BlackRock ») (NYSE : BLK), a annoncé aujourd’hui avoir mis à jour les niveaux de risque de placement des FNB iShares énumérés ci-après, avec prise d’effet en date du 19 juin 2026 :

Statement regarding the proposed issue of a prospectus

WHEATON, Ill., June 18, 2026 (GLOBE NEWSWIRE) -- Innovator Capital Management, LLC (“Innovator”), the investment adviser for the Innovator Gradient Tactical Rotation Strategy ETF and Innovator Hedged Nasdaq-100 ETF (each, a “Fund” and collectively, the “Funds”), announced today that the Funds’ Board of Trustees, at the recommendation of Innovator, has approved a plan of liquidation for each Fund (collectively, the “Plans”). Under the Plans, which are effective as of June 17, 2026, the Funds will begin the process of liquidating portfolio assets and unwinding their affairs in an orderly fashion over time. The Plans are not subject to shareholder approval.

Creates a scaled BDC positioned for growth while maintaining industry leading credit quality and portfolio yield

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.